1. Home
  2. CRGY vs PBLS Comparison

CRGY vs PBLS Comparison

Compare CRGY & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crescent Energy Company

CRGY

Crescent Energy Company

N/A

Current Price

$13.27

Market Cap

3.8B

Sector

Energy

ML Signal

N/A

Logo Parabilis Medicines Inc. Common Stock

PBLS

Parabilis Medicines Inc. Common Stock

N/A

Current Price

$29.99

Market Cap

3.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CRGY
PBLS
Founded
1986
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
3.6B
IPO Year
2022
2026

Fundamental Metrics

Financial Performance
Metric
CRGY
PBLS
Price
$13.27
$29.99
Analyst Decision
Buy
Strong Buy
Analyst Count
17
5
Target Price
$17.47
★ $41.75
AVG Volume (30 Days)
★ 5.1M
679.6K
Earning Date
11-02-2026
11-17-2026
Dividend Yield
★ 3.72%
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
★ $3,579,782,000.00
N/A
Revenue This Year
$39.29
N/A
Revenue Next Year
N/A
$222.58
P/E Ratio
$99.08
★ N/A
Revenue Growth
★ 22.14
N/A
52 Week Low
$7.68
$25.56
52 Week High
$15.47
$42.49

Technical Indicators

Market Signals
Indicator
CRGY
PBLS
Relative Strength Index (RSI) 44.05 39.57
Support Level $11.45 $26.42
Resistance Level $14.06 $33.65
Average True Range (ATR) 0.44 3.16
MACD -0.20 -0.72
Stochastic Oscillator 10.07 20.05

Price Performance

Historical Comparison
CRGY
PBLS

About CRGY Crescent Energy Company

Crescent Energy Co is an energy company committed to delivering value for shareholders through disciplined growth, acquisition ideas, and the consistent return of capital. Its long-life, balanced portfolio combines stable cash flows from low-decline production with deep, high-quality development inventory. The company operates in one reportable segment, which is the exploration and production of crude oil, natural gas, and NGLs.

About PBLS Parabilis Medicines Inc. Common Stock

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

Share on Social Networks: